Page 69 - Read Online

Meyer et al. Cancer Drug Resist 2019;2:313-25 I http://dx.doi.org/10.20517/cdr.2019.11 Page 323

translation of these findings into the clinic has demonstrated limited success, due in part to drug toxicities.
However, given the rapid development of novel epigenetic modulators, including bromodomain inhibitors,
and the growing body of literature demonstrating the efficacy of these agents in other cancers, there is
considerable potential for the future successful implementation of this therapeutic strategy in ALL.

DECLARATIONS
Authors’ contributions
Wrote the manuscript: Meyer LK, Hermiston ML

Availability of data and materials
Not applicable.

Financial support and sponsorship
This work is supported by a Genentech Foundation Fellowship Award to Meyer LK; the National Cancer
Institute (R01 CA193776) to Hermiston ML; the Buster Posey Family Foundation; the Campini Foundation;
the Pepp Family Foundation.

Conflicts of interest
Both authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Authors 2019.

REFERENCES
1. Tasian SK, Loh ML, Hunger SP. Childhood acute lymphoblastic leukemia: integrating genomics into therapy. Cancer 2015;121:3577-
90.
2. Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, et al. Genome-wide analysis of genetic alterations in acute
lymphoblastic leukaemia. Nature 2007;446:758-64.
3. Liu Y, Easton J, Shao Y, Maciaszek J, Wang Z, et al. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic
leukemia. Nat Genet 2017;49:1211-8.
4. Greaves M. In utero origins of childhood leukaemia. Early Hum Dev 2005;81:123-9.
5. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007;128:683-92.
6. Bhojwani D, Pui CH. Relapsed childhood acute lymphoblastic leukaemia. Lancet Oncol 2013;14:e205-17.
7. Baylin SB, Jones PA. Epigenetic determinants of cancer. Cold Spring Harb Perspect Biol 2016;8:a019505.
8. Luo C, Hajkova P, Ecker JR. Dynamic DNA methylation: In the right place at the right time. Science 2018;361:1336-40.
9. Wong NC, Ashley D, Chatterton Z, Parkinson-Bates M, Ng HK, et al. A distinct DNA methylation signature defines pediatric pre-B cell
acute lymphoblastic leukemia. Epigenetics 2012;7:535-41.
10. Davidsson J, Lilljebjörn H, Andersson A, Veerla S, Heldrup J, et al. The DNA methylome of pediatric acute lymphoblastic leukemia.
Hum Mol Genet 2009;18:4054-65.
11. Figueroa ME, Chen SC, Andersson AK, Phillips LA, Li Y, et al. Integrated genetic and epigenetic analysis of childhood acute
lymphoblastic leukemia. J Clin Invest 2013;123:3099-111.
12. Almamun M, Levinson BT, van Swaay AC, Johnson NT, McKay SD. Integrated methylome and transcriptome analysis reveals novel
regulatory elements in pediatric acute lymphoblastic leukemia. Epigenetics 2015;10:882-90.
13. Milani L, Lundmark A, Kiialainen A, Nordlund J, Flaegstad T, et al. DNA methylation for subtype classification and prediction of
treatment outcome in patients with childhood acute lymphoblastic leukemia. Blood 115:1214-225.
14. Sandoval J, Heyn H, Méndez-González J, Gomez A, Moran S, et al. Genome-wide DNA methylation profiling predicts relapse in